Form 4: Ekso Bionics Director, Mary Ann Cloyd, Reports Acquisition and Disposal of Shares

Sentiment:

Statement of Changes in Beneficial Ownership


Director Mary Ann Cloyd reports acquisition of restricted stock units and disposal of common stock in Ekso Bionics Holdings, Inc.

Summary

  • Mary Ann Cloyd, a director of Ekso Bionics Holdings, Inc., filed a Form 4 detailing changes in beneficial ownership of securities.
  • On June 6, 2024, Cloyd acquired 78,217 restricted stock units (RSUs) at a price of $0.
  • These RSUs represent the economic equivalent of one share of EKSO common stock and will be settled in shares upon vesting.
  • The RSUs were granted effective June 6, 2024, pursuant to an automatic annual non-employee director grant provision approved on April 13, 2021.
  • The RSUs are scheduled to vest and settle at the earlier of the date of the next Annual Meeting of Stockholders or the one-year anniversary of the Grant Date.
  • Cloyd also disposed of an unspecified amount of common stock on June 6, 2024.
  • Following these transactions, Cloyd beneficially owns 220,505 shares of common stock, including 78,217 unvested RSUs.

Sentiment

Score: 6

Explanation: The sentiment is neutral as it reflects a standard transaction related to director compensation. There are no explicit positive or negative implications.

Positives

  • The grant of RSUs to a director aligns their interests with those of the shareholders.
  • The vesting schedule encourages continued service and contribution to the company.

Future Outlook

The RSUs are scheduled to vest and settle at the earlier of the date of the next Annual Meeting of Stockholders or the one-year anniversary of the Grant Date.

Industry Context

This filing is a routine disclosure related to director compensation and equity ownership, common in publicly traded companies.

Stakeholder Impact

  • The RSU grant aligns the director's interests with those of the shareholders, potentially encouraging decisions that benefit the company's long-term value.

Key Dates

DateDescription
April 13, 2021Date the Company's Board of Directors approved the automatic annual non-employee director grant provision.
June 6, 2024Date of the transaction and the Issuer's 2024 Annual Meeting of Stockholders (the 'Grant Date').
June 26, 2024Date of the report filing.

Keywords

Form 4, Beneficial Ownership, EKSO, Ekso Bionics, Director, Mary Ann Cloyd, Restricted Stock Units, RSUs, Securities, Common Stock

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.